newsfilter
← Latest News
GlobeNewswire·

Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today